This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
healthcare: Archive
Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?
by Urmimala Biswas
BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.
AZNNegative Net Change BFLYPositive Net Change TEMNegative Net Change
artificial-intelligence earnings-outlook earnings-report healthcare medical medical-devices smart-health
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
by Kaibalya Pravo Dey
ELV outpaces UNH with stronger earnings, leaner costs and clearer guidance, making it the healthcare stock with more upside right now.
UNHNegative Net Change ELVNegative Net Change
healthcare hmo insurance medical
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
by Urmimala Biswas
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
ABTNegative Net Change MDTNegative Net Change
dividend dividend-stocks dividend-yield earnings-outlook earnings-report healthcare medical medical-devices
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
by Urmimala Biswas
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
AZNNegative Net Change IRTCNegative Net Change SOPHNegative Net Change TEMNegative Net Change
artificial-intelligence healthcare medical medical-devices smart-health
Should I Buy UnitedHealth Stock Now That it's Half-Off?
by David Bartosiak
UnitedHealth has been in serious trouble as of late. With the stock cut in half, is now the time to buy?
UNHNegative Net Change
healthcare
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
by Urmimala Biswas
CVS' pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence.
UNHNegative Net Change CINegative Net Change CVSNegative Net Change HLFNegative Net Change WBANegative Net Change
earnings-outlook earnings-report healthcare medical medical-devices retail
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?
by Urmimala Biswas
Despite trade policy challenges, Abbott's global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change
earnings-outlook earnings-report healthcare medical medical-devices
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
TXGNegative Net Change SOPHNegative Net Change TEMNegative Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical-devices
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
by Urmimala Biswas
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change
earnings-outlook earnings-report healthcare medical medical-devices
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
by Urmimala Biswas
TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?
AZNNegative Net Change IRTCNegative Net Change SOPHNegative Net Change TEMNegative Net Change
artificial-intelligence healthcare medical medical-devices pharmaceuticals
Wall Street Shaken as UnitedHealth Tanks Since Q1 Miss: Buy the Dip?
by Kaibalya Pravo Dey
From a valuation perspective, UNH appears expensive compared to its peers despite the drop in price.
UNHNegative Net Change HUMNegative Net Change ELVNegative Net Change
earnings-outlook earnings-surprise healthcare hmo insurance medical
CVS Soars 53% in Q1: Time to Buy the Stock Ahead of Earnings Release?
by Urmimala Biswas
Caremark, CVS Health's PBM business, is expected to have continued to play a vital role in offsetting the rising cost of branded drugs during the first quarter.
CVSNegative Net Change HLFNegative Net Change WBANegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices retail
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings?
by Urmimala Biswas
Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-streak earnings-surprise healthcare medical medical-devices
CVS Health vs. UnitedHealth: Which Healthcare Stock Has More Upside?
by Urmimala Biswas
CVS Health and UnitedHealth are two of the top companies leading the S&P 500 chart YTD. But which is the better investment now? Let's take a closer look.
UNHNegative Net Change CVSNegative Net Change
healthcare hospitals insurance medical medical-devices
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
ABTNegative Net Change NVONegative Net Change RMDNegative Net Change DXCMNegative Net Change EXASNegative Net Change TNDMPositive Net Change
cancer healthcare hospitals medical medical-devices oncology-screening pharmaceuticals thematic
How Should You Play UnitedHealth Stock Going Into Q1 Earnings?
by Kaibalya Pravo Dey
UNH's first-quarter earnings are likely to have benefited from growing premiums and service revenues.
UNHNegative Net Change HUMNegative Net Change MOHPositive Net Change
earnings-outlook earnings-preview healthcare hmo insurance medical
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
by Urmimala Biswas
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? Let's see.
DOCSNegative Net Change TEMNegative Net Change
artificial-intelligence computers healthcare iot medical medical-devices smart-health
UnitedHealth vs. Humana: Which Healthcare Stock Should You Buy Now?
by Kaibalya Pravo Dey
The CMS announced a hike in MA payments for fiscal year 2026, which will likely deliver a notable boost to UNH & HUM's bottom lines.
UNHNegative Net Change HUMNegative Net Change
healthcare hmo insurance insurance-premium medical
CVS Health Takes the Lead in 2025 S&P 500 Chart: Is It a Buy Now?
by Urmimala Biswas
CVS Health's strong track record of stable cash generation aids it amid the broader market sell-offs due to escalating 2025 Trump tariffs.
CVSNegative Net Change HLFNegative Net Change WBANegative Net Change
healthcare medical retail
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?
by Urmimala Biswas
Medtronic's Hypertension business is on the brink of a major expansion, driven by its Simplicity blood pressure procedure.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change NVDAPositive Net Change TSLAPositive Net Change
healthcare medical medical-devices
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy
by Urmimala Biswas
Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change
china consensus-outlook earnings-estimates-revisions earnings-outlook healthcare medical medical-devices
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
by Urmimala Biswas
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.
NVDAPositive Net Change MMSINegative Net Change STXSNegative Net Change
artificial-intelligence healthcare medical medical-devices robotics saas semiconductor
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
CGCPositive Net Change ACBPositive Net Change OGIPositive Net Change
cannabis healthcare marijuana marijuana-stocks medical
CVS Stock Soars 47% YTD: Is Digital Growth Fueling a Buy Opportunity?
by Urmimala Biswas
CVS Health is consistently increasing investments in fast-growing spaces like enterprise data platforms, cloud capabilities and digital products.
CVSNegative Net Change HLFNegative Net Change WBANegative Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook healthcare medical medical-devices retail
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
by Urmimala Biswas
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
IRTCNegative Net Change SOPHNegative Net Change TEMNegative Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook earnings-streak healthcare medical medical-devices